This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Astellas
Astellas Pharma Inc., commonly referred to as Astellas, is a leading global pharmaceutical company headquartered in Tokyo, Japan. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative medicines, Astellas focuses on areas such as oncology, urology, immunology, and neuroscience. The company is renowned for its commitment to research and development, which has led to the introduction of unique therapies that address unmet medical needs. Astellas has achieved notable market recognition, consistently ranking among the top pharmaceutical firms worldwide, thanks to its dedication to improving patient outcomes and advancing healthcare solutions.
DitchCarbon Score
How does Astellas's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astellas's score of 47 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astellas's reported carbon emissions
In 2023, Astellas Pharma Inc., headquartered in Japan (JP), reported total greenhouse gas emissions of approximately 122,250,000 kg CO2e globally. This figure includes 59,203,000 kg CO2e from Scope 1 emissions and 63,047,000 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data for this year. Astellas has set ambitious climate commitments, aiming to achieve net-zero greenhouse gas emissions by 2050. In the near term, the company targets a 63% reduction in Scope 1 and 2 emissions by FY2030, using 2015 as the base year. Additionally, Astellas aims to reduce its Scope 3 emissions by 37.5% by FY2030, also relative to the 2015 baseline. The company's emissions reduction targets are aligned with the Science Based Targets initiative (SBTi), which has validated their goals as consistent with limiting global warming to 1.5°C. Astellas's commitment to sustainability reflects its proactive approach to addressing climate change and reducing its carbon footprint across all operational scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astellas is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
